Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS
Neurology® Sep 19, 2017
Lorscheider J, et al. - The effect of disease-modifying treatment on short-term disability outcomes in secondary progressive multiple sclerosis (SPMS) was examined in this study. The authors proposed that, on average, these therapies had no significant impact on relapse-unrelated disability outcomes measured by the Expanded Disability Status Scale (EDSS) up to 4 years.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
